Are we facing a cure in lung cancer?-KEYNOTE-001 insights

被引：6
作者：
Cohen, Aharon Y.
Kian, Waleed
Roisman, Laila C.
Levitas, Dina
Peled, Nir [1 ,2 ,3 ]
Dudnik, Yulia
机构：
[1] Legacy Heritage Oncol Ctr, Oncol Div, POB 653, Beer Sheva, Israel
[2] Soroka Med Ctr, Dr Larry Norton Inst, POB 653, Beer Sheva, Israel
[3] Ben Gurion Univ Negev, POB 653, Beer Sheva, Israel
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
关键词：
CLINICAL ACTIVITY; OPEN-LABEL; PHASE IB; CANCER; PEMBROLIZUMAB; ATEZOLIZUMAB; CHEMOTHERAPY; RADIOTHERAPY;
D O I：
10.21037/atm.2019.08.87
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 15 条
  • [1] Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
    Ahn, M. -J.
    Yang, J.
    Yu, H.
    Saka, H.
    Ramalingam, S.
    Goto, K.
    Kim, S. -W.
    Yang, L.
    Walding, A.
    Oxnard, G. R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S115 - S115
  • [2] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
    Garon, Edward B.
    Rizvi, Naiyer A.
    Hui, Rina
    Leighl, Natasha
    Balmanoukian, Ani S.
    Eder, Joseph Paul
    Patnaik, Amita
    Aggarwal, Charu
    Gubens, Matthew
    Horn, Leora
    Carcereny, Enric
    Ahn, Myung-Ju
    Felip, Enriqueta
    Lee, Jong-Seok
    Hellmann, Matthew D.
    Hamid, Omid
    Goldman, Jonathan W.
    Soria, Jean-Charles
    Dolled-Filhart, Marisa
    Rutledge, Ruth Z.
    Zhang, Jin
    Lunceford, Jared K.
    Rangwala, Reshma
    Lubiniecki, Gregory M.
    Roach, Charlotte
    Emancipator, Kenneth
    Gandhi, Leena
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) : 2018 - 2028
  • [3] Pembrolizumab plus Chemotherapy in Lung Cancer
    Gil-Sierra, Manuel D.
    Fenix-Caballero, Silvia
    Alegre-del Rey, Emilio J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (11)
  • [4] A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC
    Lisberg, A.
    Cummings, A.
    Goldman, J. W.
    Bornazyan, K.
    Reese, N.
    Wang, T.
    Coluzzi, P.
    Ledezma, B.
    Mendenhall, M.
    Hunt, J.
    Wolf, B.
    Jones, B.
    Madrigal, J.
    Horton, J.
    Spiegel, M.
    Carroll, J.
    Gukasyan, J.
    Williams, T.
    Sauer, L.
    Wells, C.
    Hardy, A.
    Linares, P.
    Lim, C.
    Ma, L.
    Adame, C.
    Garon, Edward B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1138 - 1145
  • [5] Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
    Liu, Yang
    Dong, Yinping
    Kong, Li
    Shi, Fang
    Zhu, Hui
    Yu, Jinming
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [6] Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
    Mok, Tony S. K.
    Wu, Yi-Long
    Kudaba, Iveta
    Kowalski, Dariusz M.
    Cho, Byoung Chul
    Turna, Hande Z.
    Castro, Gilberto, Jr.
    Srimuninnimit, Vichien
    Laktionov, Konstantin K.
    Bondarenko, Igor
    Kubota, Kaoru
    Lubiniecki, Gregory M.
    Zhang, Jin
    Kush, Debra
    Lopes, Gilberto
    [J]. LANCET, 2019, 393 (10183) : 1819 - 1830
  • [7] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
    Paz-Ares, L.
    Luft, A.
    Vicente, D.
    Tafreshi, A.
    Gumus, M.
    Mazieres, J.
    Hermes, B.
    Senler, F. Cay
    Csoszi, T.
    Fulop, A.
    Rodriguez-Cid, J.
    Wilson, J.
    Sugawara, S.
    Kato, T.
    Lee, K. H.
    Cheng, Y.
    Novello, S.
    Halmos, B.
    Li, X.
    Lubiniecki, G. M.
    Piperdi, B.
    Kowalski, D. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) : 2040 - 2051
  • [8] Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
    Reck, Martin
    Schenker, Michael
    Lee, Ki Hyeong
    Provencio, Mariano
    Nishio, Makoto
    Lesniewski-Kmak, Krzysztof
    Sangha, Randeep
    Ahmed, Samreen
    Raimbourg, Judith
    Feeney, Kynan
    Corre, Romain
    Franke, Fabio Andre
    Richardet, Eduardo
    Penrod, John R.
    Yuan, Yong
    Nathan, Faith E.
    Bhagavatheeswaran, Prabhu
    DeRosa, Michael
    Taylor, Fiona
    Lawrance, Rachael
    Brahmer, Julie
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 116 : 137 - 147
  • [9] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Leiby, Melanie A.
    Lubiniecki, Gregory M.
    Shentu, Yue
    Rangwala, Reshma
    Brahmer, Julie R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1823 - 1833
  • [10] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
    Rittmeyer, Achim
    Barlesi, Fabrice
    Waterkamp, Daniel
    Park, Keunchil
    Ciardiello, Fortunato
    von Pawel, Joachim
    Gadgeel, Shirish M.
    Hida, Toyoaki
    Kowalski, Dariusz M.
    Dols, Manuel Cobo
    Cortinovis, Diego L.
    Leach, Joseph
    Polikoff, Jonathan
    Barrios, Carlos
    Kabbinavar, Fairooz
    Frontera, Osvaldo Aren
    De Marinis, Filippo
    Turna, Hande
    Lee, Jong-Seok
    Ballinger, Marcus
    Kowanetz, Marcin
    He, Pei
    Chen, Daniel S.
    Sandler, Alan
    Gandara, David R.
    [J]. LANCET, 2017, 389 (10066) : 255 - 265
12